ArticleBMC medicine2026
A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer's disease.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hippocampal Volume Mediates the Association Between Serum Ferritin and Cognition in Non-Dialysis End-Stage Renal Disease Patients.Brain and behavior · 2026Article
- Mechanistic research on the vestibular-hippocampal pathway in neurodegenerative diseases: an integrative perspective from molecular to behavioral levels.Frontiers in neuroscience · 2026Review
- Interpretable self-supervised transformers for resting-state EEG analysis in Alzheimer's disease.Frontiers in neuroinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPrecision medicine for Alzheimer's disease (AD) requires the development of a robust management framework grounded in individualized disease staging systems. To date, only a limited number of studies have supplemented the existing AD staging systems.
methodsThis retrospective study included 7491 MRI examinations from five independent cohorts. We used a novel pseudo-healthy synthesis method to capture individualized brain atrophy patterns. An individualized brain atrophy score (BAS) was computed from the 30 regions with the most severe brain atrophy and used to stratify participants into distinct disease stages. The Jenks natural breaks optimization method was used to determine an optimal number of disease stages based on the individual BAS.
resultsBAS exhibited a strong biological basis and revealed a synergistic relationship among biomarker-based staging systems. Four stages were delineated based on the BAS for participants with MCI and clinically diagnosed AD. Stage I showed a slight cognitive decline with only mild hippocampal atrophy evident. Stage II showed mild cognitive decline and mild brain atrophy and shrinkage, extending to the temporal and parietal lobes. Stage III showed moderate cognitive decline and more severe brain atrophy in the temporal lobe, amygdala, hippocampus, parietal lobe, and frontal lobe. Stage IV showed severe mental impairment and diffuse atrophy across the whole brain. The disease stages are associated with dementia severity and abnormalities in AD biomarkers, such as cerebrospinal fluid (CSF) Aβ
conclusionsThe individualized staging system can accurately assess disease severity, enabling risk stratification at ultra-early pathological stages and facilitating precise AD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.